



Edward J. Kessler Jorge A. Goldstein David K.S. Comwe Lawrence B. Bugaisky Donald J. Featherstone

Timothy J. Shea, Jr. Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus effrey S. Weaver Cendrick P. Patterson Eldora Ellison Floyd W. Russell Swindell

Andrea J. Kamage L Leith Bryan L. Sketton Robert A. Schwartzman John J. Figueroa Timothy A. Doyle Jennifer R. Mahalingappa Samuel L. Fox Kenneth C. Bass III

- Admitted only in Maryland
 Admitted only in Virginia
 Admitted only in Texas
 Practice Limited to

October 30, 2002

WRITER'S DIRECT NUMBER: (202) 371-2673 **INTERNET ADDRESS:** JCOVERT@SKGF.COM

Commissioner for Patents Washington, D.C. 20231

AS FILED oct. 31, 2002

Group Art Unit 1614

Re:

U.S. Utility Patent Application

Appl. No. 10/058,215; Filed: January 29, 2002

Substituted Indoles and Their Use as Integrin Antagonists

Inventors:

Lu et al.

Our Ref:

1503.1030002/JMC/THN/JSL

Sir:

Transmitted herewith for appropriate action are the following documents:

- Third Supplemental Information Disclosure Statement; 1.
- Form PTO-1449 (1 sheet) citing 1 document; 2.
- Copy of the cited document listed on Form PTO-1449 (1 document); and 3.
- Return Postcard. 4.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 † 202.371.2540: www.skgf.com

Commissioner for Patents October 30, 2002 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

John M. Covert

Attorney for Applicants Registration No. 38,759

JMC/THN/JSL/asl Enclosures

SKGF_DC1:68383.1

49

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Confirmation No. 2206

In re application of:

Lu et al.

Appl. No. 10/058,215

Filed: January 29, 2002

For:

Substituted Indoles and Their Use

as Integrin Antagonists

Art Unit:

1614

Examiner:

To be assigned

Atty. Docket:1503.1030002/JMC/THN/JSL

Third Supplemental Information Disclosure Statement

Commissioner for Patents Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Third Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Second Supplemental Information Disclosure Statement filed on September 4, 2002 in connection with the above-captioned application. A copy of this document is also provided.

Where the publication date of the listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed a publication date on the attached PTO-1449 based on

information presently available to the undersigned. However, the listed publication date should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Third Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited document and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any

overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

John M. Covert

Attorney for Applicants Registration No. 38,759

Date: Oct. 30, 2002

1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005-3934 (202) 371-2600

::ODMA\MHODMA\SKGF_DC1;67671;1 SKGF Rev 1/24/02 mac